While PSMA is a well-established biomarker for prostate cancer, previous studies have demonstrated the predictive value of SUVmax from 68Ga-PSMA-11 PET in assessing Ki-67 expression, particularly in glioma patients, where higher SUVmax values correlate with high-grade tumors14,20. This evidence concerns the gene FOLH1 and prostate cancer.